Recruiting

LuGENE®

Sponsor:

Ampel BioSolutions, LLC

Code:

NCT05845593

Conditions

Lupus Erythematosus, Systemic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Decision Support Test

Study Details

Brief summary:

This is an open label study to determine the association of the data obtained with LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE, including clinical involvement, SLEDAI score, Physician Global Assessment (PGA) and standard laboratory measures, including ANA, anti-DNA, anti-RNP and complement components C3 and C4, as well as Patient Reported Outcomes capturing pain, fatigue and Health-Related Quality of Life. The test will be administered on one occasion to patients with a clinical diagnosis of lupus or incomplete lupus and clinical and laboratory features evaluated contemporaneously. This trial includes a pilot study of approximately 10 subjects from 2-3 sites to assess whether the delivery times of LuGENE® laboratory results do not exceed more than 7 business days.

Conditions

Lupus Erythematosus, Systemic

Study ID

NCT05845593

Start date

Dec 19, 2023

Status verified date

May, 2024

Completion date

Mar 5, 2025

Anticipated

Primary completion date

Dec 10, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female aged at least 18 years old.
2. Capable of giving written consent on an IRB-approved Informed Consent Form prior to any study-specific evaluation
3. Have a clinical diagnosis of SLE determined by the examining physician or a diagnosis of incomplete lupus determined by the examining physician
4. On a stable SLE treatment regimen consisting of a stable dosage of medications for a period of at least 30 days prior to testing

Exclusion Criteria:

1. Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not related to SLE (i.e., diabetes, cardiovascular, pulmonary, hematologic, gastrointestinal, neurological, or infectious) which, in the opinion of the treating physician, could confound the results of the study or put the patient at undue risk
2. Have received intravenous glucocorticoids at a dosage of ≥ 500 mg daily within the past month
3. Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Baseline
4. Pregnant or lactating.
5. Recent participation in a clinical trial with an experimental agent in the past 6 weeks, or 5 half-lives of the study drug, whichever is longer
6. Any condition that in the opinion of the treating physician might interfere with the performance of the LuGENE® test

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Arms

Group 1

Adult male and female patients with a clinical diagnosis of SLE or incomplete lupus

Interventions

Decision Support Test

LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE

Primary outcome measure

  • LuGENE clinical decision support relative to clinical disease activity [ Time Frame: 16 months ]
  • LuGENE clinical decision support relative to lab measures [ Time Frame: 16 months ]
  • LuGENE clinical decision support relative to PROs [ Time Frame: 16 months ]

Central Contacts and Locations

Locations

Cedars-Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Principal Investigator:

Daniel Wallace

Feinstein Institute for Medical Research

Recruiting

Manhasset, New York, United States, 11030

Contacts

Principal Investigator:

Cynthia Aranow

Arthritis and Osteoporosis Consultants of the Carolinas

Recruiting

Charlotte, North Carolina, United States, 28207

Contacts

Principal Investigator:

Gordon Lam

More Information

Sponsor

Ampel BioSolutions, LLC

Last update posted

May 3, 2024

Last verified

May, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Ampel BioSolutions, LLC on 2024-05-03.